Nyvepria indication

NYVEPRIA offers the potential to help address treatment costs and was approved by the FDA based on the totality of evidence supporting high similarity to Neulasta1-3†
*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.1
NYVEPRIA does not have a designation of interchangeability with Neulasta.
WAC is a manufacturer's undiscounted or list price to wholesalers/direct purchasers and, therefore, is not inclusive of discounts to payers, providers, distributors, and other purchasing organizations.
§As of May 2020.